TY - JOUR
T1 - Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma
AU - Kreuger, Inger Z. M.
AU - Slieker, Roderick C.
AU - van Groningen, Tim
AU - van Doorn, Remco
N1 - Funding Information: The study was supported by Stichting Zeldzame Ziekten Fonds. Figure 2 was created with Biorender.com. Conceptualization: IZMK, RvD; Supervision: TvG, RvD; Visualization: IZMK, RCS; Writing - Original Draft Preparation: IZMK; Writing - Review and Editing: IZMK, RCS, TvG, RvD Publisher Copyright: © 2022 The Authors
PY - 2023/1
Y1 - 2023/1
N2 - Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss hold great potential to improve melanoma treatment. Pharmacological inhibition of the p16 targets CDK4/6 is a prime example of such a strategy. Other approaches exploit cell cycle deregulation, target metabolic rewiring, epigenetically restore expression, act on dependencies resulting from co-deleted genes, or are directed at the effects of CDKN2A loss on immune responses. This review explores these therapeutic strategies targeting CDKN2A loss, which potentially open up new avenues for precision medicine in melanoma.
AB - Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss hold great potential to improve melanoma treatment. Pharmacological inhibition of the p16 targets CDK4/6 is a prime example of such a strategy. Other approaches exploit cell cycle deregulation, target metabolic rewiring, epigenetically restore expression, act on dependencies resulting from co-deleted genes, or are directed at the effects of CDKN2A loss on immune responses. This review explores these therapeutic strategies targeting CDKN2A loss, which potentially open up new avenues for precision medicine in melanoma.
UR - http://www.scopus.com/inward/record.url?scp=85138130043&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jid.2022.07.016
DO - https://doi.org/10.1016/j.jid.2022.07.016
M3 - Review article
C2 - 36123181
SN - 0022-202X
VL - 143
SP - 18-25.e1
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 1
ER -